Kyowa Kirin expands scope of RNAi collaboration with Dicerna
This article was originally published in Scrip
Executive Summary
Satisfied with the progress of the partnership so far, Kyowa Hakko Kirin has expanded the therapeutic scope of its collaboration with Dicerna Pharmaceuticals for the R&D and commercialisation of RNAi drugs and delivery systems.